Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145997 | 0.83 | KDM4E (0.37) | KDM4EPIK3CDNAAA | |
| SCHEMBL3101220 | 0.79 | KDM4E (0.35) | KDM4EPIK3CDNAAA | |
| SCHEMBL19123212 | 0.79 | KDM4E (0.35) | KDM4EPIK3CDNAAA | |
| SCHEMBL1222082 | 0.79 | KDM4E (0.35) | KDM4EPIK3CDNAAA | |
| SCHEMBL4952545 | 0.79 | PDE3B (0.40) | KDM4EPIK3CDNAAA | |
| SCHEMBL13158292 | 0.77 | KDM4E (0.38) | KDM4EPIK3CD | |
| SCHEMBL13158266 | 0.77 | KDM4E (0.34) | KDM4EPIK3CD | |
| Hydrochloric Acid SCHEMBL28199440 | 0.77 | KDM4E (0.34) | KDM4EPIK3CDNAAA | |
| SCHEMBL22242127 | 0.76 | PIK3CD (0.39) | KDM4EPIK3CDNAAA | |
| SCHEMBL19342028 | 0.76 | KDM4E (0.33) | KDM4EPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415770-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | Emory University, Office of Technology Transfer (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4516774-A2 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | Emory University (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025016457-A1 | NEW SUBSTITUTED HETEROCYCLIC COMPOUND AS GSPTS/MYC SIGNAL FLUX REGULATOR | 杭州德睿智药科技有限公司 | 2025-01-23 | — | — | WO | disclosed |
| EP-3595652-B1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) | UNIV EMORY (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240368066-A1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | EMORY UNIVERSITY | 2024-11-07 | — | — | US | disclosed |
| US-12065402-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2024-08-20 | — | — | US | disclosed |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| US-11254680-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
| US-11225485-B2 | — | — | 2022-01-18 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| WO-2010086403-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010026113-A1 | ACYL- AND SUFONYL TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-03-11 | — | — | WO | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2104497-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008067909-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | SANOFI-AVENTIS (FR) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368066-A1 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | NR1H2, NR1H3, NR1H4 | KDM4E 2276/4885PIK3CD 3098/4885NAAA 4144/4885 |
| US-12415770-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | KDM4E 2276/4885PIK3CD 3098/4885NAAA 4144/4885 |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | KDM4E 3120/4885PIK3CD 3355/4885NAAA 217/4885 |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | NR1H2, NR1H3, NR1H4 | KDM4E 2276/4885PIK3CD 3098/4885NAAA 4144/4885 |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | KDM4E 2276/4885PIK3CD 3098/4885NAAA 4144/4885 |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH3, HRH2, HRH1 | KDM4E 697/4885PIK3CD 3808/4885NAAA 974/4885 |
| US-11225485-B2 | — | BRAF, RAF1, CDK4 | KDM4E 1847/4885PIK3CD 314/4885NAAA 3634/4885 |
| US-12065402-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | KDM4E 2276/4885PIK3CD 3098/4885NAAA 4144/4885 |
| US-11254680-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | BRAF, CDK4, RAF1 | KDM4E 1669/4885PIK3CD 140/4885NAAA 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.